The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Surgical correction of scoliosis in patients with DMD remains controversial. This retrospective study enrolled patients who underwent posterior instrumented spinal fusion to correct spinal deformity ...

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was ...

STATEN ISLAND, N.Y. -- Three-year-old Aubrey Paige Ibrahim is a beautiful little girl fighting a battle most adults would find challenging, if not impossible. Born on May 31, 2013, Aubrey was ...

Please provide your email address to receive an email when new articles are posted on . The study included 58 individuals with SMA types 2 and 3 who were treated with IV apitegromab for 52 weeks. At ...

Scholar Rock Holding Corp. (NASDAQ:SRRK) said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) ...

When Alice Wong was a baby newly diagnosed with spinal muscular dystrophy, a doctor told her parents — Chinese immigrants who’d settled in Indianapolis in the 1970s — that she may not live past the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Motor function and other motor milestones were ...

Scotland has become the first UK nation to screen all newborn babies for spinal muscular atrophy. Here is what you need to ...

The Ironman In You project aims to raise awareness on muscular dystrophy It also aims to raise money for members of the Muscular Dystrophy Association of Singapore As of June 25, this project had ...